Back to top
more

NRx Pharmaceuticals (NRXP)

(Delayed Data from NSDQ)

$2.52 USD

2.52
174,726

+0.06 (2.44%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $2.55 +0.03 (1.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 244)

Industry: Medical - Drugs

Zacks News

Zacks Equity Research

Here's Why NRx Pharmaceuticals (NRXP) Is a Great 'Buy the Bottom' Stock Now

NRx Pharmaceuticals (NRXP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Kanishka Das headshot

NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock?

NRXP is expected to provide updates on its pipeline candidates being developed for treating central nervous system disorders when it reports fourth-quarter earnings release.

Zacks Equity Research

Best Momentum Stocks to Buy for January 6th

NRXP, PDEX and PBYI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6, 2024.

Zacks Equity Research

New Strong Buy Stocks for January 6th

ALK, AHT, NRXP, PDEX and EGAN have been added to the Zacks Rank #1 (Strong Buy) List on January 6, 2024.

Zacks Equity Research

Best Momentum Stocks to Buy for December 30th

CCRD, TRDA and NRXP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2024.

Zacks Equity Research

New Strong Buy Stocks for December 30th

CCRD, APPN, USNA, TRDA and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 30, 2024.

Zacks Equity Research

New Strong Buy Stocks for December 26th

EGAN,ACMR, AVO, BB and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 26, 2024.

Zacks Equity Research

New Strong Buy Stocks for December 24th

FTI, NRXP, PBYI, POWL and VMEO have been added to the Zacks Rank #1 (Strong Buy) List on December 24, 2024.

Zacks Equity Research

NRx Pharmaceuticals (NRXP) Upgraded to Buy: Here's Why

NRx Pharmaceuticals (NRXP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors

The latest trading day saw NRx Pharmaceuticals, Inc. (NRXP) settling at $3.14, representing a +0.64% change from its previous close.

Zacks Equity Research

NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors

In the most recent trading session, NRx Pharmaceuticals, Inc. (NRXP) closed at $3.04, indicating a +0.66% shift from the previous trading day.

Zacks Equity Research

NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy: Here's What You Should Know

NRx Pharmaceuticals (NRXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

New Strong Buy Stocks for April 4th

DELL, NRXP, STEP, TCOM and PARAA have been added to the Zacks Rank #1 (Strong Buy) List on April 4, 2023.

Sweta Killa headshot

Pick These Top-Ranked Stocks to Deck Up Your Christmas Tree

We have crafted a tree with the most flourishing stocks of 2023 and the ones that are poised to soar in 2024.

Zacks Equity Research

NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock Up

NRx Pharma (NRXP) receives FDA clearance to begin clinical development for its lead candidate, NRX-101, to treat chronic pain.

Zacks Equity Research

All You Need to Know About NRx Pharmaceuticals, Inc. (NRXP) Rating Upgrade to Buy

NRx Pharmaceuticals, Inc. (NRXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Company News for Dec 30, 2021

Companies in The News Are: FCEL,CALM,NRXP,AAPL

Zacks Equity Research

Company News for Nov 30, 2021

Companies in the news are: KRYS, ADGI, NRXP, HTZ

Zacks Equity Research

IQVIA (IQV) Announces Collaboration With NRx Pharmaceuticals

IQVIA (IQV) and NRx are set to work closely to support activities essential for emergency use authorization of ZYESAMI.